<DOC>
	<DOCNO>NCT02287922</DOCNO>
	<brief_summary>The primary objective study : - To assess efficacy safety dose regimens ALX-0061 monotherapy administer subcutaneously ( s.c. ) subject active rheumatoid arthritis ( RA ) . The secondary objective study : - To assess effect ALX-0061 quality life , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) , immunogenicity ALX 0061 explore potential dose regimen ALX 0061 monotherapy , base safety efficacy , clinical development . - To obtain parallel descriptive information concern efficacy safety tocilizumab ( TCZ ) s.c. clinical trial RA population .</brief_summary>
	<brief_title>A Phase IIb Study ALX-0061 Monotherapy Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Diagnosis RA ( accord 2010 EULAR/Americal College Rheumatology ( ACR ) classification criterion ) least 6 month prior screen , ACR functional class IIII . Received previous current treatment methotrexate ( MTX ) , consider intolerant MTX , continue treatment MTX inappropriate contraindication MTX use . Subjects must receive MTX least 4 week first administration study drug . Have active RA least 6 swollen 6 tender joint ( 66/68 joint count ) time screen baseline Others define protocol Have treat DMARDs ( Disease Modifying Antirheumatic Drugs ) /systemic immunosuppressives 4 week , 12 week hydroxychloroquine , chloroquine , leflunomide ( except adequate washout procedure leflunomide complete ) , prior first administration study drug . Have receive approved investigational biological target synthetic DMARD therapy RA ( include tumor necrosis factor alphainhibitors , abatacept , rituximab , Janus kinase [ JAK ] inhibitor ) less 6 month prior screen . Have history toxicity , nontolerance , primary nonresponse inadequate response biological therapy , target synthetic DMARDs ( include JAK inhibitor ) , RA . Have receive prior therapy block interleukin6 ( IL6 ) pathway , time . Others define protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>